Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
US-Präsident setzt auf die Solana Blockchain! Diese Krypto-Perle profitiert enorm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40L1Z | ISIN: CA3499331013 | Ticker-Symbol: 7BC0
Tradegate
24.01.25
15:11 Uhr
0,416 Euro
-0,012
-2,80 %
Branche
Konsumgüter
Aktienmarkt
Sonstige
1-Jahres-Chart
FORTE GROUP HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
FORTE GROUP HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0000,00024.01.
ACCESS Newswire
296 Leser
Artikel bewerten:
(1)

Forte Group Holdings: Forte Group Announces Non-Brokered Private Placement

Finanznachrichten News

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 24, 2025 / Forte Group Holdings Inc. (CSE:FGH) (OTC:FGHFF) (FSE:7BC0, WKN:A40L1Z) ("Forte Group" or the "Company"), a diversified lifestyle and wellness consumer packaged goods company, announces that, announces a non-brokered private placement financing (the "Private Placement"), consisting of the issuance of an aggregate of 625,000 common shares of the Company (the "Shares"), at a price of $0.60 per Share for aggregate gross proceeds of up to $375,000. The Shares will be subject to a statutory hold period expiring four months and one day from the date of issuance.

The Company intends to use the proceeds of the Private Placement for general working capital and outstanding payables. Closing of the Private Placement is anticipated to occur on or about February 3, 2025.

Insiders may participate in the Private Placement and will be considered a related party transaction subject to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company intends to rely on exemptions from the formal valuation and minority shareholder approval requirements provided under subsections 5.5(a) and 5.7(a) of MI 61-101 on the basis that participation in the Private Placement by insiders will not exceed 25% of the fair market value of the Company's market capitalization. No finder's fees are payable in connection with the Private Placement.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act.

About Forte Group Holdings Inc.

Forte Group Holdings Inc. (CSE:FGH)(OTC:FGHFF)(FSE:7BC0, WKN:A40L1Z) is a diversified lifestyle and wellness consumer packaged goods company. Forte Group develops and manufactures a range of alkaline and mineral-enriched beverages and nutraceutical supplements for both its TRACE brand and private-label clients. Based in British Columbia, Canada, Forte Group owns a pristine natural alkaline spring water aquifer and operates a 40,000-square-foot, Health Canada and HACCP-certified manufacturing facility near Osoyoos, British Columbia. The Company's distribution network includes traditional retail and e-commerce channels, delivering wellness-focused products directly to consumers through its innovative offerings.

On behalf of the Board of Directors:

John Campbell,
Chief Financial Officer and Chief Strategy Officer, Director
john@fortegroup.co
604-569-1414

Disclaimer for Forward-Looking Information

This news release contains forward-looking statements within the meaning of applicable securities laws. These forward-looking statements include, but are not limited to, the Company's expectations regarding the timing and completion of the Private Placement, the use of proceeds from the Private Placement for general working capital and outstanding payables, and the anticipated participation by insiders in the Private Placement. Forward-looking statements reflect management's current beliefs, expectations, and assumptions as of the date of this release and are subject to significant risks, uncertainties, and other factors that may cause actual results to differ materially. These risks and uncertainties include, but are not limited to: the ability to complete the Private Placement in a timely manner or at all; changes in regulatory requirements and approvals; market and economic conditions; consumer demand for the Company's products; the Company's ability to generate sufficient revenue to meet financial obligations; risks associated with securing and maintaining financing; competition within the industry; and supply chain disruptions. Additionally, there are risks related to insider participation in the Private Placement and the Company's reliance on exemptions under Multilateral Instrument 61-101. The Company makes no assurance that the forward-looking statements will prove to be accurate and disclaims any obligation to update or revise these statements, whether as a result of new information, future events, or otherwise, except as required by law. For a more detailed discussion of these risks and other potential factors, please refer to the Company's public filings available on SEDAR+.

SOURCE: Forte Group Holdings



View the original press release on ACCESS Newswire

© 2025 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.